Labcorp Q2 2026 Earnings Report: Key Highlights and Investor Insights
BURLINGTON, N.C., July 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader in laboratory services, released its financial results for the second quarter ended June 30, 2026, along with an updated outlook for the full year. The company reported robust growth across all major metrics, expanded its oncology portfolio, launched innovative new products, and significantly increased its share repurchase authorization.
Key Financial Highlights
- Total Q2 Revenue: \$3.73 billion, up 5.8% from \$3.53 billion in Q2 2025.
- Q2 Diluted EPS: \$3.64, up 28.5% from \$2.84.
- Q2 Adjusted EPS: \$4.99, up 14.9% from \$4.35.
- Operating Income: \$451.6 million (OI margin 12.1%, up 90 bps); Adjusted Operating Income: \$588.7 million (AOI margin 15.8%, up 70 bps).
- Net Earnings: \$298.7 million, up from \$237.9 million.
- Free Cash Flow: \$313.9 million, with a noted decrease versus prior year primarily due to working capital timing and increased capital expenditures.
- Cash & Debt Position: \$141.8 million in cash and cash equivalents, total debt at \$5.86 billion. \$500 million in senior notes retired during Q2.
Upward Guidance Revision – 2026 Full Year
- Revenue Growth Guidance: Increased to 5.4%–6.3% (previous midpoint up 30 basis points).
- Adjusted EPS Guidance: Raised to \$18.10–\$18.55 (up 30 cents at midpoint).
- Free Cash Flow Guidance: \$1,240–\$1,360 million.
- Diagnostics Laboratories Segment: Revenue guidance raised to \$11,450–\$11,532 million; growth of 5.3%–6.0%.
- Biopharma Laboratory Services Segment: Revenue guidance raised to \$3,269–\$3,300 million; growth of 5.5%–6.5%.
Strategic and Operational Developments
- \$1 Billion Increase in Share Repurchase Authorization: Total remaining authorization now \$1.4 billion. This aggressive capital return strategy could be highly price sensitive and positively affect share value.
- Investments: \$225.7 million in acquisitions, \$353.8 million in stock repurchases, \$58.7 million in dividends paid.
- Quarterly Dividend: \$0.72 per share, payable September 11, 2026 (record date August 28, 2026).
- Acquisitions: Completed acquisition of Parkview Health’s outreach lab services (Indiana & Ohio) and Tribal Diagnostics (Oklahoma & Texas).
- Department of Defense Contract: Re-awarded to provide laboratory testing for service members and families worldwide.
Innovation & Product Launches
- Labcorp Oncology Advances:
- Advanced DPYD genotyping test for identifying patients at risk for chemotherapy toxicity.
- Nationwide launch of ColoSense®, the first FDA-approved, RNA-based at-home colorectal cancer screening test (Medicare and commercial payer coverage expanding).
- Clinical trial collaboration with Fox Chase Cancer Center for Plasma Detect Genome MRD (early-stage lung cancer recurrence risk).
- Expanded access to Roche’s VENTANA PTEN (SP21) diagnostic for prostate cancer, enabling eligibility for AstraZeneca’s TRUQAP therapy.
- Consumer Health Expansion:
- Launched Marker by Labcorp™, a direct-to-consumer genetic health panel.
- Introduced Canada’s first at-home test for women’s fertility hormones and men’s testosterone.
- Launched MyLabcorp AI-powered app for appointment scheduling, test results, and personalized health insights.
- Technology & Innovation:
- Expanded collaboration with Epic, placing 6,500+ diagnostic tests on Epic’s Aura platform.
- Enhanced patient experience at service centers, including expanded appointment availability, proactive scheduling, and reminders.
Segment Performance
- Diagnostics Laboratories:
- Revenue: \$2,900.7 million (up 5.5%), AOI margin 18.0% (up 50 bps).
- Organic growth: 3.6%, acquisitions: 1.9%.
- Adjusted operating margin increased due to organic growth and efficiencies.
- Biopharma Laboratory Services:
- Revenue: \$836.2 million (up 6.5%), AOI margin 17.0% (up 130 bps).
- Central Labs revenue growth 9.8%; Early Development revenue down 1.4%.
- Trailing twelve months (TTM) net orders: \$3.32 billion. Backlog: \$8.73 billion (up 0.2% YoY).
Balance Sheet and Cash Flow
- Assets: Total assets \$18.53 billion; goodwill \$7.03 billion; intangible assets \$3.68 billion.
- Liabilities: Total liabilities \$9.91 billion; long-term debt \$5.86 billion.
- Cash Flow: Net cash provided by operating activities \$445.5 million (Q2); capital expenditures \$131.6 million.
- Net share settlement tax payments: \$(6.3) million; stock repurchase \$(353.8) million.
Non-GAAP Adjusted Measures
Labcorp continues to report and emphasize adjusted (non-GAAP) financial metrics, including adjusted EPS, adjusted operating income/margin, and free cash flow. The company notes that these measures may differ from those used by peers and provides reconciliations to GAAP in the financial tables.
Forward-Looking Statements & Risks
Labcorp cautions investors that its forward-looking statements, including 2026 guidance, are subject to a broad range of risks, including but not limited to: regulatory changes, customer purchasing decisions, competition, global economic and geopolitical factors, inflation, and exchange rate fluctuations. Investors are advised to review Labcorp’s SEC filings for full risk disclosures.
Investor Relations
An investor presentation with further details is available on Labcorp’s investor relations website. A webcast discussing these results is scheduled for 9:00 a.m. ET and will be archived for one year.
Conclusion: Shareholder Impact
- Strong financial performance and upward guidance revision are likely to be price sensitive and could positively impact share value.
- \$1 billion increase in share repurchase authorization represents a significant capital return to shareholders and may further support share price.
- Product innovation and acquisition activity position Labcorp for long-term growth and market leadership, particularly in oncology and specialty testing.
- Dividend payment and continued disciplined capital allocation reinforce Labcorp’s commitment to shareholder returns.
- Expanded contracts and technology partnerships highlight Labcorp’s operational strength and future growth opportunities.
Disclaimer: This article is based on Labcorp’s official earnings report and related public disclosures. All forward-looking statements are subject to risks and uncertainties as described in Labcorp’s SEC filings. Investors should review official filings and consult financial advisors before making investment decisions. This article does not constitute investment advice.
